RedX Pharma Raising $17M for Antiviral, Antibody Work
LONDON RedX Pharma Ltd. is planning a £10.8 million (US$16.8 million) investment to extend the reach of its expertise in the structural modification of marketed drugs into antibiotics and antivirals.
To continue reading subscribe now to BioWorld Asia (formerly International)
Learn More about BioWorld Asia (formerly International)
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.